BRAF and Decreased total neutrophil count: In another phase II trial evaluating FOLFOXIRI + panitumumab for RAS, BRAF wild-type mCRC patients demonstrated a particularly high RR of 89% and median PFS of 11.3 months, with increased incidence and severity of neutropenia (≥ Grade 3, 48%), diarrhea (≥ Grade 3, 35%), and stomatitis (≥ Grade 3, 14%) [6].